{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:06:46Z","timestamp":1788883606863,"version":"build-2803163510"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001009","name":"Bristol Myers Squibb Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omtn.2026.103044","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T07:07:33Z","timestamp":1786518453000},"page":"103044","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunomodulatory LNP-mRNA therapeutics: The next phase of precision immuno-engineering"],"prefix":"10.1016","volume":"37","author":[{"given":"Krupal","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colt","family":"Egelston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7843-9609","authenticated-orcid":false,"given":"Tristan","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2026.103044_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41416-018-0327-z","article-title":"The clinical role of the TME in solid cancer","volume":"120","author":"Giraldo","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omtn.2026.103044_bib2","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining 'T cell exhaustion","volume":"19","author":"Blank","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omtn.2026.103044_bib3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.imlet.2017.08.010","article-title":"The potential and promise of IL-15 in immuno-oncogenic therapies","volume":"190","author":"Robinson","year":"2017","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.omtn.2026.103044_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2026.102838","article-title":"Advances in lipid nanoparticles delivering genetic medicines for solid cancers","volume":"37","author":"Yang","year":"2026","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103044_bib5","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","article-title":"T-Cell\u2013Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028","volume":"37","author":"Ott","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omtn.2026.103044_bib6","series-title":"767 Safety and preliminary efficacy of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L\/IL-23\/IL-36\u03b3 for intratumoral (ITu) injection, and durvalumab (IV) in TNBC, HNSCC, and melanoma","author":"Olson","year":"2022"},{"key":"10.1016\/j.omtn.2026.103044_bib7","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jamaoncol.2024.5927","article-title":"Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ: A Phase 1 Nonrandomized Clinical Trial","volume":"11","author":"Ramalingam","year":"2025","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.omtn.2026.103044_bib8","doi-asserted-by":"crossref","first-page":"CT004","DOI":"10.1158\/1538-7445.AM2023-CT004","article-title":"Abstract CT004: Intratumoral (IT) MEDI1191 + durvalumab (D): Update on the first-in-human study in advanced solid tumors","volume":"83","author":"Casta\u00f1\u00f3n","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtn.2026.103044_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf115","article-title":"First-in-human phase I\/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancer","volume":"30","author":"Sullivan","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.omtn.2026.103044_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.123047","article-title":"Targeted LNPs deliver IL-15 superagonists mRNA for precision cancer therapy","volume":"317","author":"Yu","year":"2025","journal-title":"Biomaterials"}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126002155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126002155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:08:41Z","timestamp":1788880121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253126002155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2162253126002155"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103044","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunomodulatory LNP-mRNA therapeutics: The next phase of precision immuno-engineering","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"103044"}}